Indian drug regulators have ordered Sun Pharmaceutical Industries to halt the manufacture, sale, and distribution of ophthalmic products at its Assam facility after a joint audit exposed serious deficiencies in quality management systems. The regulatory clampdown follows a joint inspection carried out in August by the Central Drugs Standard Control Organisation (CDSCO) and the Assam state drug regulator, which found major lapses in protocols established to ensure drug purity and patient safety. The facility was directed to freeze all ophthalmic operations immediately after authorities verified contamination in sealed medicine bottles.
Precautionary Recall of 332 Batches Across 11 Brands
The regulatory directive comes against the backdrop of Sun Pharma withdrawing around 11 brands of eye formulations from the domestic supply chain. In July, the company initiated a voluntary recall covering an estimated 332 batches of ophthalmic solutions as an initial safeguard. Regulatory documents confirm the large-scale product withdrawal, though authorities have noted that it remains undetermined whether every single recalled batch violated official pharmacopoeial benchmarks. Regulators are seeking exhaustive batch records and technical clarifications regarding the circumstances behind the withdrawals.
The list of products pulled from retail shelves includes widely prescribed formulations such as Lotepred 1% (5 ml), Nepaflac OD, Nepaflac-Z, Brinzotim, and Depopred. These eye drops are commonly recommended by ophthalmologists to manage post-surgical inflammation, ocular swelling, allergic reactions, and persistent eye infections. Regulatory scrutiny escalated after reports of adverse reactions surfaced, with patients developing serious secondary eye infections following product administration. Subsequent laboratory tests conducted by enforcement agencies verified that sealed, unopened bottles taken from distribution channels carried bacterial contamination, prompting regulators to probe how non-sterile units cleared manufacturing line controls.
Patient Safety Alerts Raised Over Contaminated Formulations
Quality concerns surrounding the company’s ophthalmic output had drawn formal medical scrutiny prior to the state inspection. In June, the All India Ophthalmological Society issued a safety advisory alerting clinicians and the public to quality defects detected in certain batches of Predmiet eye drops. Dr. Santosh Honawar, general secretary of the medical body, confirmed that several patients had developed infections linked directly to the application of the medicine. Independent laboratory tests conducted on sealed commercial units confirmed breaches of sterility parameters, prompting Sun Pharma to initiate product recalls for the flagged production lots.
Because ophthalmic preparations bypass mucosal barriers and enter ocular tissue directly, any microbial impurity poses risks of vision impairment or systemic complications. Medical experts and regulators emphasized that maintaining aseptic environments during sterile filling, strict particulate control, and end-line microbial testing remain mandatory legal obligations rather than procedural formalities.
Compliance Report Under Scrutiny Following Earlier Regulatory Actions
Sun Pharma has formally submitted a detailed compliance and corrective action report to authorities, which is currently undergoing regulatory review. However, company representatives did not respond to queries seeking comment on the specific infractions detected at the Assam plant or the full scope of the product recalls. According to regulatory officials, operational clearance for the facility remains conditional upon the verification of all corrective measures outlined in the report.
The intervention in Assam adds to the regulatory pressures previously encountered by the drugmaker. Last year, the United States Food and Drug Administration placed export restrictions on Sun Pharma’s manufacturing plant in Halol, Gujarat, citing persistent quality assurance failures and contamination control lapses. While ophthalmic drugs represent roughly 3 percent of the company’s annual domestic revenues, the regulatory intervention in Assam highlights ongoing scrutiny over sterile drug production across domestic pharmaceutical manufacturing plants.
